Trading Information Summary - On August 15, 2025, the main capital inflow for Lizhu Group was 39.34 million yuan, while retail and speculative capital saw outflows of 28.72 million yuan and 10.62 million yuan respectively [1][3]. Company Announcement Summary - Lizhu Group received the acceptance notice from the National Medical Products Administration for the domestic production registration of JP-1366 tablets, an innovative potassium ion competitive acid blocker (P-CAB) for treating gastroesophageal reflux disease [1][3]. - The clinical study for JP-1366 included 362 patients and demonstrated that its efficacy in esophageal mucosal healing was non-inferior to that of the comparator drug, Naisan, while significantly improving symptoms such as heartburn and reflux [1][3]. - Cumulative R&D expenses for JP-1366 reached approximately 185.21 million yuan as of the announcement date [1]. - According to IQVIA data, the domestic terminal sales for P-CAB are projected to be approximately 1.25 billion yuan in 2024, reflecting a year-on-year growth of 81.22%, with Q1 2025 sales estimated at around 394.35 million yuan, also showing an 81.63% increase year-on-year [1].

Core Viewpoint - Lijun Group's JP-1366 tablet has received acceptance for its domestic production drug registration application, indicating progress in its development pipeline for treating gastroesophageal reflux disease [1][2] Company Announcements - Lijun Group's JP-1366 tablet registration application was accepted by the National Medical Products Administration, with a cumulative R&D investment of approximately RMB 185.21 million [1] - The company has initiated a Phase III clinical study for JP-1366, involving 362 patients, showing non-inferiority in esophageal mucosal healing rates compared to the control drug, Naisan [2] Market Performance - As of August 15, 2025, Lijun Group's stock closed at RMB 40.1, a 0.25% increase from the previous week, with a total market capitalization of RMB 36.254 billion [1] - The stock reached a weekly high of RMB 40.75 and a low of RMB 39.26, ranking 15th in the chemical pharmaceutical sector and 453rd among A-shares [1] Sales Projections - According to IQVIA data, the domestic terminal sales for P-CABs are projected to reach approximately RMB 1.248 billion in 2024, reflecting a year-on-year growth of 81.22%, with Q1 2025 sales estimated at RMB 394.35 million, up 81.63% year-on-year [2]